As a proud first-generation Jordanian American, Dalal Nesheiwat learned early on that resilience is strengthened by those who believe in you. Discover how those lessons shaped her leadership journey and why she's committed to paying that support forward.
Cancer research and development is a dynamic and ever-evolving field. One significant area of focus is the role of HER2.
The Galien Foundation has recognized Daiichi Sankyo’s HER2 directed antibody drug conjugate (ADC) with the prestigious 2024 Prix Galien USA Award for Best Biotechnology Product.
For cancer patients, the science concerning their disease is sometimes outside of reach. As a patient-centric organization, we are on a mission to break down those barriers.
Cancer remains one of the most challenging diseases in the world today, but critical advances in science are transforming options for more personalized treatment.
A career of building hope for people with cancer began with a single childhood moment for our Vice President, Global Team Leader, Oncology Research & Development, Dalila Sellami, MD.
As a teenager volunteering at a hospital, Simon King, Chief People Officer at Daiichi Sankyo, Inc., learned the difference between listening with his ears and listening with his heart.